// App-Quantinova.ai

: Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN.

Researchers

Presenter

  • Shun Tezuka

Principal Investigators

  • Riu Yamashita

  • Satoshi Horasawa

  • Takao Fujisawa

  • Kentaro Sawada

  • Ayumu Yoshikawa

  • Yoshiaki Nakamura

  • Kumiko Umemoto

  • Nobuhiro Shibata

  • Koushiro Ohtsubo

  • Shinji Itoh

  • Akiko Todaka

  • Kentaro Sudo

  • Masayuki Furukawa

  • Masafumi Ikeda

  • Chigusa Morizane

  • Makoto Ueno

  • Takayuki Yoshino

Medical Centers

  • National Cancer Center East, Japan, Chiba, Japan, Japan

  • National Cancer Center Hospital East, Japan, Kashiwa, Chiba, Japan

  • Department of Hepatobiliary-Pancreatology, National Hospital Organization, Kyushu Cancer Center, Kyushu, Japan

  • Kanagawa Cancer Center, Yokohama, Japan

  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan

  • Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • Translational Research Support Section, National Cancer Center Hospital East, Kashiwa, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan

  • Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

  • Division of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan

  • Department of Pharmacy, St.Marianna University School of Medicine, Kawasaki, Japan

  • Kansai Medical University Hirakata Hospital, Hirakata, Japan

  • Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan, Chiba, Japan

  • Kyushu University Department of Surgery and Science, Fukuoka-Shi Higashi-Ku, Japan

  • Kushiro Rosai Byoin, Kashiwa-Shi, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Japan, Shizuoka, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Adrucil injection

  • Gemcitabine

  • Oxaliplatin

  • Irinotecan

  • leucovorin

  • Paclitaxel

  • FOLFIRINOX

  • Cisplatin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved